Alumis (NASDAQ:ALMS) Major Shareholder Foresite Capital Management Vi Purchases 190,500 Shares

Alumis Inc. (NASDAQ:ALMS) major shareholder Foresite Capital Management Vi bought 190,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was bought at an average cost of $6.56 per share, for a total transaction of $1,249,680.00. Following the completion of the transaction, the insider directly owned 2,542,003 shares of the company’s stock, valued at approximately $16,675,539.68. The trade was a 8.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Foresite Capital Management Vi also recently made the following trade(s):

• On Tuesday, November 18th, Foresite Capital Management Vi bought 117,374 shares of Alumis stock. The stock was bought at an average price of $6.19 per share, with a total value of $726,545.06.
• On Monday, November 17th, Foresite Capital Management Vi purchased 200,000 shares of Alumis stock. The stock was bought at an average price of $5.59 per share, for a total transaction of $1,118,000.00.

Alumis Stock Up 2.5%

Shares of NASDAQ ALMS traded up $0.16 during trading on Wednesday, hitting $6.57. 1,624,729 shares of the company traded hands, compared to its average volume of 821,277. The firm has a market capitalization of $683.67 million, a P/E ratio of -1.62 and a beta of -1.33. The company has a 50-day moving average price of $4.61 and a 200-day moving average price of $4.23. Alumis Inc. has a 1 year low of $2.76 and a 1 year high of $10.49.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. Research analysts predict that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Analyst Ratings Changes

ALMS has been the subject of a number of research analyst reports. Morgan Stanley dropped their target price on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a research note on Thursday, November 13th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Alumis in a research report on Thursday, August 14th. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Wells Fargo & Company assumed coverage on shares of Alumis in a research report on Friday, July 25th. They set an “overweight” rating and a $17.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Alumis has a consensus rating of “Moderate Buy” and a consensus price target of $19.20.

Institutional Trading of Alumis

A number of hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Alumis by 320.9% during the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after purchasing an additional 4,894 shares in the last quarter. Kera Capital Partners Inc. purchased a new stake in Alumis during the 2nd quarter worth $32,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Alumis by 199.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after buying an additional 7,165 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after buying an additional 7,467 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new position in Alumis in the 2nd quarter valued at about $36,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.